Phaseline

Companies › AUG Therapeutics

AUG Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AVTX-803–Phase 3Leukocyte Adhesion DeficiencyNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05462587AVTX-803Phase 3Leukocyte Adhesion DeficiencyImmunologyNov 2026
NCT05754450AVTX-803Phase 3Leukocyte Adhesion DeficiencyImmunologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Pharvaris Netherlands Lynk Pharmaceuticals Fujian Mindong Rejuvenation Pharmaceutical Jiangsu Genscend Biopharmaceutical TRB Chemedica

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.